OTC Pravachol Use Among Rx Patients Needs More Study, FDA Cmte. Says
Executive Summary
The reason individuals switch from taking prescription cholesterol-lowering agents to OTC Pravachol (pravastatin) in actual use studies should be the subject of additional research, FDA advisory committee members suggested to Bristol-Myers Squibb July 14.
You may also be interested in...
Statin Studies May Dampen Enthusiasm For Cost-Effectiveness Trials – AARP
Results of the head-to-head comparison of Pfizer's Lipitor and Bristol-Myers Squibb's Pravachol may reduce industry's enthusiasm for comparative studies, AARP CEO Bill Novelli said
Statin Studies May Dampen Enthusiasm For Cost-Effectiveness Trials – AARP
Results of the head-to-head comparison of Pfizer's Lipitor and Bristol-Myers Squibb's Pravachol may reduce industry's enthusiasm for comparative studies, AARP CEO Bill Novelli said
Bristol OTC Pravachol Study Enrollment Does Not Match Indication - FDA
Bristol-Myers Squibb may need to better demonstrate consumers' ability to make self-selection choices based on appropriate cholesterol levels in order to convince FDA that an OTC version of Pravachol is approvable.